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Vitamin D Deficiency May Increase Cardiovascular Risks
Agrowing body of data suggests that low 25-hydroxyvitamin D levels, present in30% to 50% of the population, may adversely affect cardiovascular health by
activating the renin-angiotensin-aldosterone system and possibly by increasing insulin
resistance. Epidemiologic studies have associated low vitamin D levels with both
coronary risk factors and adverse cardiovascular outcomes. Large, randomized con-
trolled trials are needed to determine if vitamin D supplementation reduces cardiovas-
cular end points. For the time being, Lee and colleagues recommend measuring
vitamin D levels and appropriate supplementation for musculoskeletal health pending
the results of trials on cardiovascular events. See page 1949.
Page 1965
Interventional Cardiology
Impact of Diabetes on the Results of the ARTS-II Trial
The ARTS-I (Arterial Revascularization Therapies Study–Part I) trial randomizedpatients with multivessel disease to either percutaneous coronary intervention
(PCI) with bare-metal stents (BMS) or coronary artery bypass graft surgery (CABG).
The ARTS-II trial utilized similar entry criteria, but the PCI was performed with
sirolimus-eluting stents (SES). This paper focuses on how diabetes altered the out-
comes of patients at 3 years. In nondiabetic patients, the incidence of the primary
composite end point, which included repeat revascularization (major adverse cardio-
vascular and cerebrovascular events [MACCE]), was significantly lower in patients
receiving SES than BMS and similar to patients assigned to CABG. In diabetic
patients, the incidence of MACCE with SES was similar to both the BMS and CABG
groups, but the incidence of death/cerebrovascular accident/myocardial infarction was
significantly lower than in the BMS group. In summary, at 3 years, PCI using SES for
patients with multivessel disease appears to be safer and more efficacious than BMS and
similar to CABG, irrespective of the diabetic status of the patient. See page 1957.
See figure.
Page 1972
Antiplatelet Therapy
Diabetic Patients Have Reduced Thienopyridine
Efficacy Because of Decreased Conversion of Prodrug
Erlinge and colleagues evaluated the prevalence and mechanism of poor responsive-ness to thienopyridines in patients with and without diabetes. The proportion of
patients with poor responsiveness was greater in the clopidogrel group for all definitions
and at all time points. Poor responders had significantly lower plasma levels of the active
metabolite (AM) and were more likely to have diabetes. When the AM was added to
blood prior to testing, poor responders showed normal responsiveness. The mecha-
nism of incomplete platelet inhibition in clopidogrel poor responders is lower plasma
levels of its AM and not differences in platelet P2Y12 receptor function. See pages
1968 and 1978. See figure.
(continued on page A-30)
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The Efficacy of the Italian Pre-Participation Screening Program for Athletes
Twenty-five years ago, Italy mandated that all athletes participating in competitivesports undergo a standardized pre-participation screening program performed by
a specially-trained physician, including a 12-lead electrocardiogram. Corrado and
colleagues provide details on the Italian program through a retrospective, observational
analysis. Approximately 10% of screened patients were referred for subsequent testing,
usually an echocardiogram. The rate of athlete disqualification doubled during this
time to approximately 2%. There was a remarkable drop in the rate of sudden death in
athletes, from 3.6 per 100,000 to 0.4 per 100,000. This analysis demonstrates that this
strategy can reduce the incidence of sudden death related to athletic participation.
See pages 1981 and 1997.
Screening of Athletes
Differences in Pre-Participation Screening Guidelines
Both the American Heart Association and the European Society of Cardiology(ESC) have established consensus guidelines for eligibility/disqualification deci-
sions in competitive athletes with cardiovascular abnormalities. Pelliccia and colleagues
provide a detailed comparison between the 2 guidelines, highlighting some of the key
differences. For instance, while both documents agree that hypertrophic cardiomyop-
athy increases the risk of death and that affected athletes should be proscribed from
competition, the European guidelines recommend that family members with the same
mutation, but no evidence of hypertrophy, also be excluded. There are also differences
in the acceptable length of the QT interval corrected for heart rate in patients suspected
of long QT syndrome. Some of the discrepancies emanate from social and legal
variances, but the authors suggest that attempts should be made to broker a unified
statement to avoid confusion. See pages 1990 and 1997.
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Heart Failure
Candesartan Is Safe and Effective in Heart Failure Patients With Low BP
Meredith and colleagues investigated the efficacy and tolerability of candesartan,according to baseline blood pressure (BP), in the almost 5,000 patients with a
low ejection fraction (EF) (40%) in the CHARM (Candesartan in Heart failure:
Assessment of Reduction in Mortality and morbidity) program. Low systolic blood
pressure (SBP) at baseline predicted worse clinical outcomes, but did not modify the
positive effects of candesartan on clinical outcomes. For both placebo and candesartan,
study drug discontinuation for adverse effects (especially hypotension) was highest in
patients with the lowest SBP, but the relative risk of discontinuation was not increased
in patients with a low baseline BP. In patients with systolic dysfunction, the relative
risks and benefits of candesartan were not altered by low BP. See page 2000.
See figure.(continued on page A-32)
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Cardiac Imaging
Caffeine Attenuates Adenosine-Induced Perfusion
Defects and Can Be Mitigated by High Dose Adenosine
Adenosine provokes coronary vasodilation via the arteriolar A2A adenosine recep-tors; methylxanthines, including caffeine, competitively inhibit adenosine recep-
tors. Reyes and colleagues repeated adenosine myocardial perfusion scintigraphy
(MPS) studies in patients who abstained from caffeine for 12 h prior to their initial
study. Before the second study, subjects ingested 200 mg of caffeine, the equivalent of
2 cups of coffee. Caffeine reduced the magnitude of the perfusion defect (summed
difference score [SDS] 12 at baseline vs. 4 after caffeine). Some patients were given a
larger dose of adenosine (210 g/kg/min compared with the standard dose of 140
g/kg/min); with this dose, there was no reduction in SDS. This study confirms that
caffeine attenuates adenosine-induced perfusion abnormalities and shows that this
attenuation can be overcome with a higher dose of adenosine. See page 2008.
See figure.
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Pre-Clinical Research
A Novel Tracer Allows SPECT Imaging of Myocardial Fibrosis
Van den Borne and colleagues used a mouse model of myocardial infarction (MI)to test the ability of a novel radiolabeled tracer to identify and quantify areas of
active myocardial fibrosis. The tracer, Cy5.5-RGD imaging peptide (CRIP), binds to
integrins such as v3, which is expressed by myofibroblasts, and also binds to
procollagen I. The specificity of the tracer was confirmed by histopathology. Maxi-
mum CRIP uptake was observed in the infarct area and was highest at 2 weeks post-MI.
Uptake was reduced by treatment with captopril and losartan. Radiolabeled CRIP
allows for noninvasive visualization of interstitial myocardial fibrosis. See pages
2017 and 2029. See figure.
